Four ways to work with us
Clinical assets
We license clinical assets that already show proof of concept (beyond Phase 1), with options for joint development to take the asset forward in the region.
Recently approved products
Drugs approved by the USFDA or EMA, including small molecules, biologics and gene-editing therapies, with continued post-marketing clinical development where needed.
Commercial assets
Branded generics, generics, biosimilars, biobetters and any asset that can improve access to therapy for patients in the region.
In-licensing & out-licensing
Out-licensing connects you with partners in MENA through our network of pharma companies, medtech start-ups and research institutions. In-licensing helps you find the right regional partner, with deal structures customized to your needs.
Why license through AcedrA?
- A pipeline-tracking practice covering more than 1,000 biotech and medical companies
- Regulatory, medical and distribution capabilities under one roof
- Local presence in Saudi Arabia, the UAE and Tunisia
- A hybrid model: we can both develop and commercialize
Start a licensing conversation
Tell us about your asset or what you are looking for.